Smith MR, et al. - This trial was designed to gauge the efficacy of apalutamide in men with non-metastatic castration-resistant prostate cancer at high risk for the development of metastasis. Apalutamide therapy led to substantially longer metastasis-free survival and time to symptomatic progression among men with non-metastatic castration-resistant prostate cancer when compared to placebo.